Mirtazapine for Appetite Stimulation: Do Not Use
Based on the highest quality evidence, mirtazapine should NOT be used for appetite stimulation in cancer patients, as it has been shown to be no better than placebo in randomized controlled trials. 1
Evidence-Based Recommendation
The 2023 ASCO guideline explicitly states that mirtazapine 15 mg once nightly was no better than placebo for cancer-related anorexia and cachexia 1. This represents the most recent, high-quality guideline evidence directly addressing this question and should guide clinical practice.
Alternative Agents to Consider Instead
Since mirtazapine is ineffective, consider these evidence-based alternatives:
First-line option:
- Olanzapine 2.5 mg once daily is now recommended by ASCO for appetite stimulation and weight gain in advanced cancer patients 1
- In controlled trials, 60% of patients gained >5% body weight versus 9% with placebo
- Also improved appetite and reduced chemotherapy toxicity
- This represents the strongest current evidence for pharmacologic appetite stimulation
Second-line options (if olanzapine not tolerated):
- Megestrol acetate: Minimum effective dose is 160 mg daily, which appears optimal 2
- Corticosteroids: Short-term trial for appetite stimulation 1, 2
- Medroxyprogesterone acetate (MPA): Minimum 200 mg daily 2
Why Mirtazapine Fails for Appetite
While the FDA label notes that appetite increase occurs in 17% of patients treated with mirtazapine (versus 2% placebo) 3, this side effect profile from depression trials does not translate to therapeutic benefit in cancer-associated anorexia. The 2021 double-blind RCT specifically testing mirtazapine 15 mg for cancer cachexia found no significant difference versus placebo in appetite improvement 4.
Dosing Context from FDA Label
If mirtazapine were to be used (which is not recommended for appetite based on evidence):
- Standard starting dose: 15 mg once daily at bedtime 3
- Maximum dose: 45 mg daily
- The FDA label documents appetite increase as an adverse effect, not a therapeutic indication 3
Critical Caveats
Important safety considerations if mirtazapine is prescribed for any reason:
- Significant somnolence occurs in 54% of patients 3
- Weight gain ≥7% occurred in 7.5% in depression trials 3
- QTc prolongation risk, especially with other QT-prolonging drugs 3
- Drug interactions requiring dose adjustment with CYP3A4 inhibitors/inducers 3
The evidence is clear: prioritize olanzapine 2.5 mg daily for appetite stimulation in cancer patients, not mirtazapine 1.